300255 Stock Overview
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.49 |
| 52 Week High | CN¥25.88 |
| 52 Week Low | CN¥7.56 |
| Beta | 0.086 |
| 1 Month Change | 8.13% |
| 3 Month Change | 103.48% |
| 1 Year Change | 57.01% |
| 3 Year Change | 152.34% |
| 5 Year Change | 284.43% |
| Change since IPO | 404.83% |
Recent News & Updates
Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Oct 30
Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%
Oct 08Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Recent updates
Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Oct 30Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%
Oct 08Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01Shareholder Returns
| 300255 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.1% | -1.9% | -1.2% |
| 1Y | 57.0% | -1.8% | 11.8% |
Return vs Industry: 300255 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 300255 exceeded the CN Market which returned 11.8% over the past year.
Price Volatility
| 300255 volatility | |
|---|---|
| 300255 Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300255's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300255's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,410 | Hao Cai | www.hbcsbio.com |
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. It offers crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadri heparin calcium API, nandroparin calcium injection, and dalteparin sodium API and injection.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Fundamentals Summary
| 300255 fundamental statistics | |
|---|---|
| Market cap | CN¥18.83b |
| Earnings (TTM) | -CN¥844.59m |
| Revenue (TTM) | CN¥1.05b |
17.9x
P/S Ratio-22.3x
P/E RatioIs 300255 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300255 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.05b |
| Cost of Revenue | CN¥1.59b |
| Gross Profit | -CN¥536.35m |
| Other Expenses | CN¥308.24m |
| Earnings | -CN¥844.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -50.85% |
| Net Profit Margin | -80.07% |
| Debt/Equity Ratio | 92.6% |
How did 300255 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 00:19 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Qiang | China International Capital Corporation Limited |
| Xiaoyan Wang | China Minzu Securities |
| Hai Zhu Peng | Huatai Research |